Current literature suggests that strong WT1 expression in a carcinoma of unknown origin virtually excludes a breast primary. Our previous pilot study on WT1 expression in breast carcinomas has shown WT1 expression in approximately 10% of carcinomas that show mixed micropapillary and mucinous morphology (Mod Pathol 2007;20(Suppl 2):38A). To definitively assess as to what subtype of breast carcinoma might express WT1 protein, we examined 153 cases of invasive breast carcinomas. These consisted of 63 consecutive carcinomas (contained 1 mucinous tumor), 20 cases with micropapillary morphology (12 pure and 8 mixed), 6 micropapillary 'mimics' (ductal no special type carcinomas with retraction artifacts), 33 pure mucinous carcinomas and 31 mixed mucinous carcinomas (mucinous mixed with other morphologic types). Overall, WT1 expression was identified in 33 carcinomas, that is, 22 of 34 (65%) pure mucinous carcinomas and in 11 of 33 (33%) mixed mucinous carcinomas. The non-mucinous component in these 11 mixed mucinous carcinomas was either a ductal no special type carcinoma (8 cases) or a micropapillary component (3 cases). WT1 expression level was similar in both the mucinous and the non-mucinous components. The degree of WT1 expression was generally weak to moderate (490% cases) and rarely strong (o10% cases). None of the breast carcinoma subtype unassociated with mucinous component showed WT1 expression.
Among normal human tissues, Wilms' tumor (WT1) protein is expressed at high levels in kidney glomeruli, gonadal ridge of developing gonads, sertoli cells of the testis, and both epithelial and granulosa cells of the ovary, suggesting a developmental role in both the genital system and kidney. 1, 2 WT1 gene is located on chromosome 11p13, and is primarily involved in the development of Wilms' tumor.
3 WT1 immunoreactivity (for the C-terminal end) is also seen in desmoplastic small round cell tumor. However, in an immunohistochemical work up of a carcinoma of unknown primary in an adult, WT1 is considered to be a highly sensitive and specific marker of mullerian serous carcinoma of ovarian, tubal, or primary peritoneal origin. [4] [5] [6] [7] It is also highly expressed in normal and malignant mesothelium. 8 Overexpression of WT1 mRNA in different types of hematological malignancies and solid tumors has been observed in recent studies. [9] [10] [11] [12] Current clinical trials have demonstrated WT1 becoming a molecular target for cancer immunotherapy; thus, its immunohistochemical detection in tumor cells is of clinical importance. 13, 14 Immunohistochemical expression of WT1 has been demonstrated in a few breast carcinomas in some recent studies. 6, 11 However, its expression in the different subtypes of invasive breast carcinoma has not been extensively studied. In a recent study by Lee et al, 15 WT1 nuclear expression was demonstrated in a minority of invasive micropapillary carcinomas. In a pilot study performed at our institution on WT1 expression in primary invasive breast carcinomas, we identified WT1 expression in 10% of tumors that showed mixed (MX) mucinous and micropapillary morphology. 16 However, most of the pure micropapillary carcinomas were negative for WT1 and, in contrast, one pure mucinous carcinoma showed moderate degree of WT1 nuclear expression. This observation led us to examine WT1 expression in large numbers of pure and MX mucinous carcinomas of the breast.
In the current study, we have examined immunohistochemical expression of WT1 in a series of invasive breast carcinomas comprising of pure and MX mucinous types, pure and MX micropapillary types, and over 60 cases of consecutive breast carcinomas.
Materials and methods

Case Selection
The study was reviewed and approved by the Institutional Review Board. Cases were selected from the archives of the Department of Pathology at the Magee-Womens Hospital, University of Pittsburgh Medical Center. A total of 153 cases of invasive breast carcinomas were examined for WT1 expression in this study. Case selection was not random and can be grouped as follows:
Group 1 (n ¼ 63): These were 63 cases of consecutive invasive breast carcinomas. Of these, 54 (86%) were ductal, including one pure mucinous carcinoma and nine (14%) lobular carcinomas.
Group 2 (n ¼ 26): Cases in this group were retrieved by searching our pathology database of invasive breast carcinomas for 'micropapillary' and 'micropapillary features.' The cases were reclassified as pure invasive micropapillary carcinoma (n ¼ 12), MX no special type (hereby referred as 'ductal' only) and micropapillary (n ¼ 6), MX micropapillary and mucinous (n ¼ 2), and remainder as ductal with retraction artifacts (n ¼ 6). The classification was performed using previously defined criteria and also influenced by immunohistochemical staining for EMA. [17] [18] [19] Group 3 (n ¼ 64): This group consisted of either pure mucinous carcinomas (n ¼ 33) or carcinomas with MX mucinous and non-mucinous component (n ¼ 31). The MX carcinoma group consisted of 25 MX mucinous and ductal carcinomas, 5 MX mucinous and micropapillary carcinomas and 1 MX carcinoma with mucinous, micropapillary, and papillary morphology.
Tissue Microarray
Tissue microarrays (TMAs) with threefold redundancy were created for each group of cases. Three to six tissue cores each with a core diameter of 0.6 mm punched from representative tumor regions of each donor block were transferred and arrayed into a new recipient paraffin blocks using a tissue microarrayer (Beecher Instruments, Sun Prairie, WI, USA). Group 1 cases (consecutive breast carcinoma) were arrayed on TMA-1, group 2 cases (micropapillary) were arrayed on TMA-2, group 3 pure and MX (with both mucinous and non-mucinous components) mucinous carcinomas were arrayed on TMA-3A and TMA-3B.
Immunohistochemistry
All TMA sections were subjected to immunohistochemical staining for WT1 (clone 6F-H2, predilute; Cell Marque, Hot Springs, AR, USA). TMA-2 was also stained with EMA (E29, predilute; Ventana Medical Systems, Tucson, AZ, USA).
Four microns TMA sections were immunostained on the Benchmark s XT automated stainer (Ventana Medical Systems). The WT1 protocol consisted of a pretreatment with CC1, pH 8.0, combined with protease III (Ventana Medical Systems) followed by incubation with WT1 mouse monoclonal antibody. The antigen-antibody complexes were detected using an iVIEWt DAB detection kit (Ventana Medical Systems).
EMA was used only as an adjunct for correct classification of cases in the micropapillary TMA (TMA-2). EMA staining was performed using the same platform as WT1 and required no pretreatment. All cases classified as either pure micropapillary or with micropapillary component showed 'reverse polarity' with EMA.
Scoring
Hormone receptor studies were performed at the time of initial diagnosis. Estrogen and progesterone receptors were scored using a semiquantitative scoring system similar to previously described H-score methodology. 20 This method takes into account percentage as well as intensity of staining. The percentage of positive cells was multiplied by the intensity of staining (0, 1 þ , 2 þ , or 3þ ), followed by addition of all the values. Therefore, the score ranged from 0 (no staining) to 300 (diffuse strong staining). A score of 11 or more was considered as positive. The positive staining was further subdivided into weak (score of 11-50), moderate (score of 51-199), and strong (score of 200 or more) expression for statistical analysis. HER2 was considered as positive if tumor showed a 3 þ immunohistochemical score or gene amplification by fluorescence in situ hybridization.
WT1 staining was also assessed using a criterion similar to the hormone receptors and the positive staining was similarly subdivided into weak (score of 11-50), moderate (score of 51-199), and strong (score of 200 or more). Only nuclear WT1 staining was scored. The rationale behind this subdivision was that ovarian serous carcinomas generally show a WT1 score of 200 or more, and our intent was to determine whether WT1 staining in breast carcinoma would cause a problem in differential diagnosis with ovarian tumors in a metastatic setting.
Cellularity Assessment
All available tumor slides were reviewed. For pure mucinous carcinomas, the percentage of mucin (without cells) was subtracted from the entire tumor (100%) to calculate percentage tumor cellularity. For MX carcinomas, the percentage of mucinous carcinoma (both mucin and cells floating within mucin) was subtracted from the entire tumor (100%) to calculate the percentage of non-mucinous component.
Statistical Analysis
Statistical analysis was performed using the Arcus Quickstat software program (Longman Software Publishing, Cambridge, England). The differences between WT1-positive and WT1-negative tumors (in both pure and MX mucinous carcinoma subtypes) with respect to known prognostic variables were analyzed using w 2 /Fisher's exact test. Statistical significance was defined as a P-value less than 0.05.
Results
WT1 expression in various breast tumor subtypes is summarized in Table 1 . Among the group of consecutive breast carcinomas (group 1), only 1 of 63 (1.6%) cases showed WT1 expression. This tumor was a pure mucinous carcinoma. Among the micropapillary group (group 2), 2 of 20 (10%) tumors showed WT1 expression. Both tumors showed a MX micropapillary and mucinous morphology and WT1 expression was seen in both components ( Figure 1 ). All ductal tumors with retraction artifacts in group 2 (six in number) were negative for WT1. The tumors that showed WT1 expression were predominantly from group 3 (mucinous tumors). They were either pure mucinous carcinomas or tumors that show MX morphology comprising of mucinous and non-mucinous components. Among the pure mucinous carcinomas, overwhelming majority of cases (21/33; 64%) showed WT1 nuclear expression (Figure 2 ). WT1 immunohistochemical score ranged from 15 to 210, with a mean score of 88.6 and a median score of 90. Using a three-tiered scoring system (discussed in the Materials and methods section), 7 cases showed weak WT1 expression (33%), 13 cases showed moderate WT1 expression (62%), and only 1 case showed strong WT1 expression (5%). In this group of pure mucinous carcinoma, WT1 expression was significantly associated with low Nottingham grade (P ¼ 0.01) and lower percentage cellularity (P ¼ 0.01). The result for other variables was not statistically significant (Table 2) .
Among the MX (mucinous and non-mucinous) carcinomas in group 3, WT1 nuclear expression was identified in 9 of 31 (29%) cases. The WT1 immunohistochemical score for this group ranged from 20 to 220, with a mean score of 99.4 and a median score of 80. Using a three-tiered scoring system, three cases showed weak WT1 expression (33%), five cases showed moderate WT1 expression (56%), and only one case showed strong WT1 expression (11%). Of these nine MX carcinomas positive for WT1, eight were MX mucinous and ductal carcinomas, and one was a MX mucinous, micropapillary, and papillary carcinoma. The WT1 immunohistochemical score in the mucinous and non-mucinous component was similar in seven cases ( Figure 3 ) and in two cases, mucinous component stained slightly stronger than the nonmucinous component. Similar to pure mucinous carcinoma group, WT1 expression was again significantly associated with low Nottingham grade (P ¼ 0.04) and patient aged more than 55 years. The result for other variables was not statistically significant (Table 3 ). 
Discussion
This is the first comprehensive study that has analyzed WT1 expression in breast carcinoma subtypes. We convincingly demonstrate that WT1 expression in breast carcinomas is predominantly seen in mucinous carcinomas. The expression is seen in up to two-third of pure mucinous carcinomas and in approximately one-third of MX mucinous carcinomas. When expression is seen in MX carcinomas, the non-mucinous component is generally a no special type ductal carcinoma or a micropapillary carcinoma. However, all 18 pure micropapillary carcinomas and MX micropapillary carcinomas with ductal carcinomas in our study were negative for WT1 expression. Recently, Lee et al 15 reported WT1 expression in invasive micropapillary carcinomas. They analyzed 34 cases and found weak to moderate expression in 1-10% of the cells in 9 cases. It appears that many, if not all, of these cases would be considered negative by our criteria (a score of 11 considered positive). Therefore, we do not believe that there is any discordance between our study and Lee et al's study, but it is rather the effect of a more stringent and objective scoring criteria in our study that is responsible for this subtle difference. Unfortunately, Lee et al did not examine mucinous carcinomas for WT1 expression.
We also analyzed WT1 expression with respect to various clinical-pathological parameters. WT1 expression showed statistically significant association with lower tumor grade and lower percentage tumor cellularity in pure mucinous carcinoma (Table 2) . For MX carcinomas, WT1 expression was associated to lower tumor grade and older age ( Table 2 ). There was no correlation with hormone receptor status, tumor size, nodal status, and HER2 expression.
WT1 expression in mucinous breast carcinomas in itself is a novel and surprise finding, and the similar degree of WT1 expression in the nonmucinous component is even more intriguing. Studies have shown a relatively poor prognosis of the MX mucinous carcinomas compared to pure mucinous carcinomas. 21 It is possible that the subset of these MX mucinous tumors that show WT1 expression are more closely related to pure mucinous carcinomas than to the non-mucinous component would otherwise suggest. A prime 18, 22 We believe this issue should be further analyzed in context of WT1 expression, especially because of statistically significant association between WT1 expression and low tumor grade. In our current study, there were a total of eight MX mucinous and micropapillary carcinomas. Of these, five were negative for WT1 and three were positive for WT1. Of the five tumors negative for WT1, lymph node status was available on three cases and all had lymph node metastases (two pN1mi, one pN1). Of the three WT1-positive cases, one case was negative for lymph node metastasis and the other two showed micrometastasis. These case numbers are too small to make any meaningful conclusion, but a larger data set need to be analyzed in conjunction with WT1 expression.
A similar degree of WT1 expression in the nonmucinous component of a MX carcinoma is of some concern for the differential diagnosis in a carcinoma of an unknown primary site. As mentioned earlier, we analyzed our results using a semiquantitative method that enable us to address this important issue. Our results show that a total of 33 carcinomas were positive for WT1 expression. Of these 33, only 2 (6%) tumors showed strong WT1 expression, that is, an immunohistochemical score of 200 or more. In contrast, majority (B90%) of non-endometrial mullerian serous carcinomas show diffuse strong WT1 expression. 4, 5 Therefore, the degree of WT1 expression can still help differentiate between a breast primary and a mullerian primary tumor. Only caveat is that endometrial serous carcinomas can show WT1 expression in approximately 20% of cases and majority of these tumors would show only moderate expression of WT1 protein. 23, 24 WT1 gene has been widely accepted to have a tumor suppressor role in the formation of Wilms' tumor, but in other solid tumors, some recent studies have suggested an oncogenic role. 25, 26 The exact reason for WT1 expression in mucinous breast carcinoma remains uncertain, but we speculate an oncogenic role of WT1 protein because of its expression in one particular morphologic type of tumor and absence of WT1 expression in normal breast luminal epithelium.
Another aspect of WT1 expression in any malignant tumor is that it raises some hope regarding treatment. With the confirmed expression of WT1-derived peptides on malignant cell surfaces and the recognition of these peptides by cellular and humoral immune responses, several studies suggest that WT1 may be a promising potential target antigen in immunotherapeutic trials. 13, 14, [27] [28] [29] [30] [31] As far as mucinous breast carcinoma is concerned, WT1 immunotherapy appears to be an attractive targeted therapy as these tumors occur predominantly in the elderly population, where the choice of safe chemotherapeutic regimen is rather limited. However, it is still not clear if these patients with relatively indolent tumor type might benefit.
In summary, WT1 expression in breast carcinoma is seen predominantly in the mucinous subtype. The degree of expression is generally moderate and therefore would not be a major issue in the differential diagnosis from an ovarian primary, especially if combined with other breast-specific markers. 32 With the advent of use of WT1 peptide immunotherapy in malignancies, expression of WT1 in mucinous breast carcinomas provides a molecular target in these relatively indolent breast tumors.
